性的少数者のHIV行動を改善するための行動経済的介入
性的少数者のHIV関連行動を改善するための行動経済的介入の開発
This research study is testing a new behavioral therapy called Episodic Future Thinking or EFT can help people reduce drug use and risky sexual behaviors while helping them adhere to their HIV prevention medication (PrEP). Participants will be randomly assigned to one of two groups. One group will receive standard care, which includes counseling on HIV prevention, drug use reduction, and sexual health. The other group will receive standard care plus a new program called Episodic Future Thinking (EFT), where participants will think about and plan for their future goals using a mobile app and counseling sessions. Study procedures that are not part of regular care include filling out surveys, providing blood, urine, and swab samples for testing, and using the EFT app.
調査の概要
詳細な説明
Phase 1 of the study will involve a formative evaluation of the Episodic Future Thinking (EFT) intervention among (n=10) sexual minority individuals (SMIs) utilizing qualitative interviews. (This phase of the study data will not be reported on ClinicalTrials.gov, since it is not part of the randomized controlled trial).
Phase 2 of the study will utilize a two-arm pilot randomized controlled trial of Episodic Future Thinking plus standard of care (intervention) vs. standard of care only (control) condition to improved HIV-related behaviors (PrEP adherence, sexual risk behaviors and methamphetamine use) among sexual minority individuals.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Emeka Okafor, PhD, MPH
- 電話番号:210-450-7377
- メール:okaforcn@uthscsa.edu
研究場所
-
-
Texas
-
San Antonio、Texas、アメリカ、78229
- 募集
- University of Texas Health Science Center at San Antonio
-
コンタクト:
- Chukwuemeka N Okafor, PhD, MPH
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults 18 - 34 years of age
- HIV negative (assessed via Rapid HIV Antibody Test)
- Identify as gay, or bisexual
- Recent (past 3 months) methamphetamine use
- Currently prescribed and taking HIV PrEP medication
- Self-reported HIV PrEP nonadherence in the past three months
- Urine screen test for PrEP nonadherence
- Self-reported condomless anal sex or a STI in the past three months
- Able to attend all study visits
- Fluent in English
Exclusion Criteria:
- Currently receiving treatment for any substance use disorder,
- HIV positive
- Having a medical or psychiatric illness that in the opinion of the PI would interfere with study participation
- Unable to provide informed consent
- Unable to attend protocol directed study visits
- Any plans that would preclude study completion (e.g. surgery, major medical treatments such as chemotherapy, incarceration, travel/moving out of San Antonio, Texas)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Episodic Future Thinking App
EFT is a behavioral economic intervention designed to improve decision-making by reducing delay discounting and improving demand. The EFT intervention will be administered through a combination of in-person counseling sessions and mobile health (mHealth) technology via an app platform. |
Participants who meet the eligibility criteria will receive the EFT intervention, a cognitive training exercise designed to help them generate and visualize future events or goals. The intervention will be administered individually, in person, by a trained counselor
他の名前:
|
|
介入なし:Control Group
Standard of Care: The standard of care group will receive brief information and supportive counseling around PrEP adherence, methamphetamine use reduction and engaging in safe sexual behaviors. Participants will also receive counseling on a topic of concern identified by the participant. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dried Blood Spot Analysis for STI adherence
時間枠:Day 1 to Day 180
|
Blood spots will be collected and assessed for sexually transmitted infections (STI). |
Day 1 to Day 180
|
|
Urine Collection for Drug Screening
時間枠:Day 1 to Day 180
|
Urine will be tested for drug screening. Number of subjects that result in a negative drug screening will be reported. |
Day 1 to Day 180
|
|
Urine Collection for Sexually Transmitted Infections (STIs) and Pre-exposure Prophylaxis (PrEP) adherence
時間枠:Day 1 to Day 180
|
Urine will be tested for STIs. Number of subjects that test negative for STIs will be reported. |
Day 1 to Day 180
|
|
Rectal Swab for STI testing
時間枠:Day 1 to Day 180
|
A rectal swab will be obtained for STI. Number of subjects that test negative for STIs will be reported. |
Day 1 to Day 180
|
|
Pre-exposure Prophylaxis (PrEP) Related Intentions
時間枠:Day 1 to Day 180
|
A 3-item scale to measure PrEP-related intentions (e.g., "During the next three months, I will talk to a health care provider about PrEP"; "During the next three months, I will seek out more information about PrEP" and "During the next three months, I will get a prescription for PrEP"). Response options will be 1 = No, definitely not; 2 = No, probably not; 3 = Yes, probably and 4=Yes, definitely. A total range of scores is 3-12 with a higher score indication a greater intention of taking preventative measures. |
Day 1 to Day 180
|
|
PrEP Attitudes
時間枠:Day 1 to Day 180
|
A 5-item scale to evaluate attitudes regarding PrEP use (e.g., "People who take PrEP are responsible"; "Taking PrEP is safe"). Response options will range from 1=strongly disagree to 5=strongly agree. Total scores will range between 5 and 25, with higher scores indicating more favorable attitudes toward PrEP use. |
Day 1 to Day 180
|
|
PrEP Stigma
時間枠:Day 1 to Day 180
|
A 5-item scale to assess PrEP stigma (e.g., "People who take PrEP are promiscuous"). Responses will be on a 5-point scale, ranging from 1=strongly disagree to 5=strongly disagree. The total range of scores is 5-25, where higher scores denote greater stigma associated with PrEP. |
Day 1 to Day 180
|
|
PrEP Self-efficacy
時間枠:Day 1 to Day 180
|
Participants will self-report the level of difficulty they anticipate in performing 8 behaviors associated with PrEP use (e.g., "How difficult would it be for you to seek out more information about PrEP to decide if it is right for you?"). Responses will be on a scale from 1=very hard to do to 4=very easy to do. Total scores range from 8-32, where higher scores suggest higher levels of self-efficacy. |
Day 1 to Day 180
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rapid HIV test
時間枠:Day 30 to Day 180
|
Test for HIV infection. Number of negative results will be reported. |
Day 30 to Day 180
|
|
Delayed Discounting
時間枠:Day 1 to Day 180
|
Delay discounting tasks will consist of 1) a standard adjusting-amount monetary tasks presenting repeated choices between various amounts of money now ($0 to $1,000) and $1,000 after a fixed delay (1 day to 25 years); 2) a cross-commodity task presenting choices between various amounts of methamphetamine now and money later in which the values are made equivalent with the monetary task; and 3) a condom delay discounting task assessing the likelihood that the participant would have sex with their ideal partner immediately with no condom vs. with a condom following a delay. Delayed discounting rate (or k) is an index of the devaluation of a rewards over time, with higher k values representing steeper discounting rates and a greater preferences for immediate rewards. |
Day 1 to Day 180
|
|
Demand
時間枠:Day 1 to Day 180
|
Demand tasks will consist of hypothetical purchasing tasks assessing 1) Methamphetamine demand (grams of methamphetamine purchased as a function of increasing price); 2) condom demand (likelihood of purchasing condoms as a function of increasing price, with the follow-up question of whether they do not have sex or have sex without a condom when the likelihood of condom purchasing goes to zero); and 3) PrEP demand (likelihood of purchasing a one-month supply of PrEP as a function of increasing price). Demand data will be fit to an exponentiated demand model: Q=Q0*10k(e-αQ0C-1), where Q represents consumption/use of the commodity as a function of increasing cost (C). |
Day 1 to Day 180
|
|
Diagnostic and Statistical Manual of Mental Disorders (DSM)-5-TR Self-rated Level 1
時間枠:Day 1 to Day 180
|
This adult version of the measure consists of 23 questions that assess 13 psychiatric domains, including depression, anger, mania, anxiety, somatic symptoms, suicidal ideation, psychosis, sleep problems, memory, repetitive thoughts and behaviors, dissociation, personality functioning, and substance use. Each item inquires about how much (or how often) the individual has been bothered by the specific symptom during the past 2 weeks. Each item on the measure is rated on a 5-point scale (0=none or not at all; 1=slight or rare, less than a day or two; 2=mild or several days; 3=moderate or more than half the days; and 4=severe or nearly every day). Scoring: Scoring can be done at three levels: Item Level: Review individual item scores. Domain Level: Sum item scores within each domain. Full Survey Level: Sum all item scores. |
Day 1 to Day 180
|
|
Generalized Anxiety Disorder Screener (GAD-7)
時間枠:Day 1 to Day 180
|
The GAD-7 will be used to assess generalized anxiety symptomology. This is a 7-item measure that asks participants to rate the frequency with which they have been bothered by anxiety symptoms within the past two weeks on a scale ranging from 0 ("not at all") to 3 ("nearly every day"). Scores on all items are summed up to obtain a total severity score between 0 and 28. Scores reflect no significant anxiety symptoms (0-4), mild anxiety symptoms (5-9), moderate anxiety symptoms (10-14), and severe anxiety symptoms (>15) |
Day 1 to Day 180
|
協力者と研究者
捜査官
- 主任研究者:Emeka Okafor, PhD, MPH、The University of Texas Health Science Center at San Antonio
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- STUDY00000869
- R34DA060078 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Publication policy will focus on ensuring that all dissemination of research findings from this study is conducted in an accurate, transparent and ethical manner. Authorship will be determined based on significant contributions to the study's conception, design, data acquisition, analysis or interpretation as well as in drafting and critically revising the manuscript. During this review process any potentially identifiable information will be carefully reviewed and anonymized if necessary.
IPD 共有時間枠
Summary results will be published through ClinicalTrials.gov and the study results will be published in a peer review journal after study completion and data analysis.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。